Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q3 2018 · 10-Q
Revenue$6.22K$6.22K−36.2% vs Q3 2017 Net Income-$1.33M-$1.33MN/M vs Q3 2017 EPS Diluted-$0.02-$0.02N/M vs Q3 2017 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,052,108N/M Margins · derivedGross margin49.0%−34.2 pt vs Q3 2017
Operating margin-15035.8%−2891.4 pt vs Q3 2017
Net margin-21428.3%−4604.1 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 14, 2018 · 45 d after period end